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Current strategies for cancer patient management include the use of genomic and proteomic test results to help guide
therapeutic selection. The need for multi-target variant analysis is highlighted by the growing number of novel therapies
to treat tumors with specific profiles and the increasing recognition that cancer is an extremely heterogeneous syndrome.
Microarray analysis is a powerful genomic tool that provides genome-wide genetic information that is critical for guiding
cancer treatments. Unlike constitutional applications of microarray analysis which are performed on whole blood samples,
microarray analysis of solid tumors is challenging because tumor tissues are typically formalin fixed and paraffin embedded
(FFPE). Genomic DNA extracted from FFPE tissues can also be fragmented into small pieces and yield much lower
concentrations of DNA. We validated and implemented the Affymetrix OncoScan® FFPE assay to enable genome-wide
analysis from these types of samples. The Affymetrix OncoScan® assay utilizes molecular inversion probes that generate
multiplexed array hybridization targets from as short as 40 base-pairs of sequence and as low as approximately 80 ng of
genomic DNA. OncoScan microarray analysis provides genomic information that includes structural variations, copy
number variations and SNPs in a timely and a cost-effective manner from FFPE tumor tissues.
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Cancer is a polygenic and multifactorial genetic syndrome
characterized by many different forms of molecular vari-
ants including somatic mutations and copy number varia-
tions (CNVs) [1]. Identification of CNVs and somatic
mutations are critical for determining diagnosis, prognosis
and therapeutic selection for any given patient.
Chromosomal microarray analysis (CMA) enables
simultaneous detection of variations in cancers at a
genome-wide level, compared to detection of a limited
number of genes and gene variants by fluorescence in situ
hybridization (FISH), realtime-PCR, and Sanger sequen-
cing [2, 3]. CMA can be divided into two major categories
[2]: first is a two-color experiment also referred to as array
Comparative Genomic Hybridization (aCGH), in which
patient and normal samples are differentially labeled and
hybridized to probes on a single microarray, and second is
a one-color experiment also known as single nucleotide
polymorphism (SNP)-based microarray or SNP-array in* Correspondence: Gregory.J.Tsongalis@hitchcock.org
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population of normal samples and used as a reference for
the patient sample [4]. The two-color analysis generates
results as a signal ratio, while most of the one-color assays
provide absolute signal intensity information [2]. The
aCGH consists of CNV probes, while SNP-arrays have
mainly SNP probes. While the CNV probes provide only
CNV information, SNP-arrays generate both SNP
genotype and CNV information using the signal intensity
to generate CNV information [5, 6]. The combined use of
CNV and SNP probes is ideal for maximal coverage and
high resolution in detection of these variants [5].
Genome-wide analysis for human cancers is technic-
ally challenging due to several inherent variables with
the sample type [7]. DNA extraction from solid tumor
tissues in the clinical setting usually requires methods
for nucleic acids to be extracted from formalin-fixed,
paraffin-embedded (FFPE) samples. These sample types
result in genomic DNA (gDNA) which is degraded into
smaller fragments. In addition, the yield of extracted
gDNA may be low due to the amount of starting
material available, especially in biopsy specimens. Ale is distributed under the terms of the Creative Commons Attribution 4.0
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eity of tumor tissues where there is a presence of normal
cells whose DNA could dilute out that of the tumor
cells. A robust microarray assay should be applicable to
low quantity and quality of gDNA and have analytical
tools to discern information from cancer cells versus
that of normal cells.
To overcome these obstacles, microarray protocols
can be modified to accommodate FFPE tumor speci-
mens [8]. Among them, the OncoScan® FFPE Assay Kit
(Affymetrix, a Thermo Fisher Scientific company) is the
first microarray designed specifically for use with
degraded DNA as is found in FFPE tissue. The Oncos-
can array utilizes SNP probes to provide copy number as
well as allele frequency information [8–10]. Here we
discuss utilization and implementation of the OncoScan
microarray, including generation of targets from gDNA
prepared from FFPE samples, microarray hybridization,
data analysis, and quality control.
The OncoScan® FFPE assay
The OncoScan assay is an accepted cancer diagnostic
microarray for detection of CNVs, loss of heterozygosity
(LOH), and cancer-related somatic mutations [11]. The
OncoScan array allows genomic analysis of almost all sam-
ple types regardless of source and sample age [6, 12, 13].
Previously these types of samples were cumbersome with
other genomic assays owing to poor quality and quantity of
extracted gDNA. The OncoScan assay, however, incorpo-
rates unique ways of target generation, array hybridization,
and data analysis, which make the assay significantly less
dependent on gDNA quality and quantity.
Quantification of gDNA sample
Following gDNA extraction from FFPE samples, a
critical quality assurance metric is to accurately quantify
concentrations of nucleic acid. Coming from FFPE
tissue, these gDNA samples are likely to be fragmented
into smaller pieces and possibly contaminated with other
nucleotides and RNA. Because of this, DNA specific
quantification methods using fluorescent dyes should be
used instead of the more common absorbance spectro-
photometric methods [14]. Quantitative PCR (qPCR)
may be an even more accurate way to quantify FFPE-
extracted gDNA despite taking longer time than the
fluorescent dye method [14]. In our experience quantifi-
cation of gDNA by qPCR showed better correlation with
probe amplification rates than that of the dye methods.
Molecular inversion probe technology
The OncoScan microarray has incorporated the Molecular
Inversion Probe (MIP) technology to generate targets,
which hybridize to probes on the OncoScan microarray.
gDNA is hybridized for 16–18 h with CNV and somaticmutation probe mixes (Fig. 1a). While 80 ng gDNA is rec-
ommended by the manufacturer, our data suggests using
quantities of FFPE-extracted gDNA as low as 30 ng will
generate excellent data. Others have reported using much
less than that amount of gDNA while still able to produce
high-quality results [10].
Each MIP probe has two homology regions for
hybridization to a gDNA target region with a gap in
between them (Fig. 1a) [15]. Each homology region is 20
base-pairs long; hence, the probe set can hybridize frag-
mented gDNA as short as 40 base-pairs [16]. This
feature makes MIP less dependent on high-quality of
gDNA compared to other genomic technologies that
require relatively longer intact gDNA. Directions of the
homology regions in the probe are designed to generate
an incomplete circular form between the gDNA target
and the probe.
Following the overnight hybridization, the incomplete
circular probe and gDNA mixes are equally divided into
two tubes (Fig. 1b) [16]. To each tube, a mix of A and T
nucleotides or a mix of G and C nucleotides is added to
fill the gap. Depending on the nucleotide in the gap, a
group of probes will be present in the completed circular
form, while other probes will remain as incomplete cir-
cular forms. Exonucleases, which are specific for linear
DNA, digest excess probes as well as incomplete circular
forms of probes, and gDNA (Fig. 1c). Following the
digestion step, there are two tubes per sample and each
of the tubes harbors circular forms of probes, which
have been gap-filled either with A/T or G/C.
Within the probe, there are two cleavage sites, and a
set of PCR primer sites (Fig. 1a) [15]. A mix of cleavage
enzymes recognizes one of the cleavage sites to generate
a linear form of the probe from the circular form
(Fig. 1d). A significant difference between the unpro-
cessed and processed (gap-filled) probes is the direction
of PCR priming sites (Fig. 1a and d). In the unprocessed
probes, PCR priming sites face outward and away from
each other; therefore, no PCR products are amplified. In
contrast, PCR products are amplified from gap-filled and
cleaved probes because these processes make the PCR
priming sites face each other (Fig. 1e). This inversion of
PCR priming sites makes MIP unique because it
provides greater selectivity for amplification of desired
targets. In addition, the primer sequences are designed
for optimal amplification in terms of priming
temperature and secondary structure without non-
specific amplification from gDNA sequences.
An additional critical part of the MIP technology is a
tag sequence that plays the role of a barcode for a
specific gDNA target region (Fig. 1a and d) [15]. The
homology region sequences hybridize to a specific
gDNA target region (Fig. 1a) so that they should be
complementary to each other. The tag sequence is an
Fig. 1 The Molecular Inversion Probe: Target Generation and Hybridization Procedures a Annealing: Probe and gDNA hybridization; b Gap filling with A/T
or G/C nucleotides; c Exonuclease selection for gap filled probes; d Cleavage at site 1 for probe opening and inversion; e Probe amplification and
biotinylation; f Cleavage at site 2 to release the tag sequence; f Array hybridization followed by staining with phycoerythrin through the biotin-streptavidin
interaction; g Array scanning. Yellow and white colors indicate presence and absence of the phycoerythrin fluorescence signal, respectively. (See text
for details)
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target according to a specific homology region in a
probe. Thus, the tag sequences are unique to the
assigned genomic DNA region. The tag sequences are
the only part involved in the hybridization to targets onmicroarrays. PCR products are digested with another
restriction enzyme to separate the tag sequence (with a
forward priming site) from the remaining sequence
including homology regions (Fig. 1f ). Each tag sequence
region is designed for optimal hybridization with
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increase the efficiency of the assay (Fig. 1g). During
PCR, biotin-labeled nucleotides are incorporated into
the product (Fig. 1e). Following hybridization, the biotin
is bound by phycoerythrin through serial staining of a
streptavidin-phycoerythrin conjugate and an anti-
streptavidin biotinylated antibody (Fig. 1g). Phycoeryth-
rin fluorescence signal is recorded by the Affymetrix
GeneChip® Scanner (Fig. 1h).
The OncoScan assay is designed to utilize two micro-
arrays per sample [16]. In the gap filling step, mixturesFig. 2 Principles of Copy Number and B-allele Frequency Calculation and Prese
gain, loss and copy-neutral loss of heterozygosity (LOH) are displayed in a segm
single-nucleotide polymorphism (SNP). Blue and red lines represent chromosom
SNP4 ~ 7 is generated by acquisition of additional mother’s chromosome segm
inherited only from father. The copy-neutral LOH indicated by SNP11 ~ 13 has d
allele and letter “B” does for a minor allele. Genotypes of major (A) alleles are de
are done by the G/C OncoScan microarray. Circles represent probes, and intens
white color for no signal through orange and pink to red color for the greatest
the normalized signal intensities of sample at each probe by those of the refe
G/C channel signal intensity is counted, while on heterozygous probes, signa
it is displayed as a base 2 logarithm. Normal or seemingly normal of two cop
than zero, respectively. c B-allele frequency (BAF) is calculated by dividing the
alleles. In normal sample, three values of 1, 0.5, and 0 are obtained. A gain reg
allelic imbalance. Loss and loss events followed by duplication such as unipar
intermediate values if the sample is homogeneous for cancer burdenof probe and gDNA duplexes are divided into two
reactions for A/T- and G/C-gap filling. These two reac-
tion products are individually hybridized in two separate
reactions but to the same microarray (Fig. 2a). Original
OncoScan assays had been designed to use four individ-
ual nucleotides in the gap filling and four microarrays to
determine genotypes at all SNPs [6, 15]. With the loss of
detecting A-to-T and G-to-C SNPs of CNV probes, the
number of gap filling reactions and microarrays has been
reduced to two. Now OncoScan assays detect A/T-to-G/C
SNPs (A-to-G, A-to-C, T-to-G, and T-to-C), whichntation in the OncoScan Microarray Analysis a Copy number variations of
ent of artificial chromosomes. Numbers mark the position of each
es from father and mother, respectively. The gain region represented by
ent. The loss region detected by SNP8 ~ 10 has a chromosome segment
uplicated father’s chromosome segments. Letter “A” stands for a major
termined by the A/T OncoScan microarray, while those of minor (B) alleles
ities of fluorescence signal are presented by different colors in the order of
intensity in this presentation. b Copy number is determined by dividing
rence at the corresponding probe. On homozygous probes, either A/T or
l intensities of both channels are included in the calculation. In the graph,
y numbers have zero values. Gain and loss have higher and lower values
signal intensities of minor (B) allele by those of major (A) plus minor (B)
ion generates four values (e.g., 0, 0.33, 0.67, and1) and it is interpreted as
ental disomy have LOH, and BAF at each probe has either 0 or 1 without
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hybridization signals from both arrays, it indicates that it
is heterozygous for an SNP position (Fig. 2a). If there are
hybridization signals only from one array and not from
the other, it reflects that it is homozygous for the SNP
position. To obtain allelic information, the OncoScan
assay assigns the A/T array as the major allele and the G/C
array as the minor allele.
The OncoScan assay utilizes 335,000 probes for CNVs
and allele frequencies, and 541 probes for cancer som-
atic mutations [10]. Scanning takes approximately 7 min
per microarray or 14 min per sample. The entire testing
process is completed within 48 h. Scanning generates
DAT files, and the Affymetrix GeneChip Command
Console software converts them to CEL files [11]. The
DAT files are scanned array probe imaging files, and the
CEL files are array fluorescence intensity files. The CEL
files are then used for data analysis.
Data analysis
The OncoScan analysis procedure includes obtaining
data stored in CEL files, signal normalization, deter-
mination of CNVs, calculation of the B-allele fre-
quency (BAF), detection of LOH, and identification of
somatic mutations.
The OncoScan microarray is an SNP-array and its
performance was optimized as a one-color microarray
experiment [2, 16]. Using the SNP-array, only a single
patient’s gDNA sample is processed and hybridized to
the probe sets on the microarray. A reference signal
data from a normal population is required, and the
OncoScan uses a reference data set from 400 normal
FFPE samples of various sources including different
geographic locations, genders, age groups, and tissue
types [17]. CNVs are computationally detected by
dividing the normalized signal intensity of the sample
by that of the reference data [4]. The computation is
displayed as the base 2 logarithm of the quotient of
the division (Fig. 2b and Fig. 3).
If gDNA were extracted from either pure cancer or
pure normal cells, the data analysis would be more
straightforward. However, in almost all tissue samples,
normal cells are present adjacent to cancer cells, from
which DNA may also be extracted; therefore CNV
estimation is challenging. To overcome this issue,
OncoScan has employed the Tumor Scan™ (TuScan™)
algorithm. If a sample consists of pure cancer or normal
cells, TuScan™ returns an output of “homogeneous” and
it can be interpreted as either 100% cancer or 100% nor-
mal cells based on the CNV results [11]. If cancer cells
constitute the majority of the sample compared to nor-
mal cells, e.g., if cancer cells are nearly homogeneous,
the TuScan™ algorithm subtracts the normal cell data
from the CNV estimation and calculates CNV only inthe tumor component as an integer number (e.g., CN = 2)
with a burden of cancer as the percentage of aberration
(%AC) [11, 18]. Because the integer number is only from
cancer cells, CNVs between samples can be compared
regardless of different amounts of normal cells. If samples
are too heterogeneous, so that it is not feasible for the
TuScan™ algorithm to isolate cancer cell information from
normal, %AC is reported as “NA” and the algorithm calcu-
lates average CNV of all cells in the sample, and provides
CNV as a value with two decimal digits of 0.33 increments
(e.g., 2, 2.33, 2.66, etc.) [17, 19].
BAF is calculated by dividing the number of minor (B)
alleles by the sum of major (A) and minor (B) alleles
[20]. OncoScan generates allelic information. A/T is
assigned to the major allele (A), and G/C is considered
the minor allele (B) (Fig. 2c). Thus, if there are signals
only at the probe in the A/T array, BAF at a probe
position equals 0. If there are signals only at the probe in
the G/C array, BAF is 1. BAF of 0.5 is obtained if there are
signals in both A/T and G/C arrays at the probe position.
For each probe position of normal cells, a BAF value is
given as one of these three (Fig. 2c and Fig. 3).
When the values are displayed across an entire
chromosome, they appear as three tracks (Fig. 3). Be-
cause each allele is from one of two biological parents,
the chances of AA, BB, and AB genotypes are equal. If
patients acquire additional chromosomes or segments,
the BAF would have more than three tracks; for
example, four tracks would indicate allelic imbalance
(Fig. 2c and Fig. 3b). If a patient loses a segment of
chromosome, alleles are either A or B in the absence of
AB so that the BAF is either 0 or 1; therefore, probes are
distributed into two categories, which are displayed as
two tracks. This phenomenon is called LOH (Fig. 2c and
Fig. 3b). The two-track cases, however, are observed only
if cancer cells are homogeneous. Otherwise LOH shows
four tracks. It is possible that two chromosomes come
from a single parent. In this case, it looks normal as the
copy number is 2; however, the BAF shows LOH
because these chromosome regions are identical. This is
called copy-neutral LOH (Fig. 2c). Taken together,
combined analysis of CNV and BAF provides more in-
formation than CNV alone [20].
To facilitate OncoScan data analysis, the Nexus
Express is used to convert TuScan™ algorithm-processed
results to graphics with multiple levels and various sec-
tions (Fig. 3) [10]. All chromosomes of a single patient
can be displayed simultaneously (Fig. 3a), and individual
chromosome can also be presented with more detailed
information (Fig. 3b). CNV and BAF are displayed along
a chromosome where positions of cancer related genes
are marked (Fig. 3b). The application also allows com-
parison of multiple test results to discern common and
unique variations in population studies [3, 21].
Fig. 3 Analysis Presentation by the Nexus Express OncoScan Software a The Nexus Express software presents Copy Number (CN) (top panel) and BAF
(bottom panel) on all chromosomes of a single patient. All chromosomes are color-coded, and tracks consist of dots, which are calculated CN or BAF
values at corresponding SNP positions. b The software also displays CN and BAF on an individual chromosome with detailed information. Blue and red
bars around the chromosome image represent gain and loss, respectively. LOH is marked by orange colored bars. In the CN graph, each dot represents
CN values, which are calculated from signal intensities of a sample compared to those of a normal reference. CN values from loss regions are negative,
while those from gain regions are positive on the logarithm 2 graph. Consistent with the whole chromosome image, loss regions are highlighted by
red, while gain regions are marked with blue color. In the BAF graph, dots are from division of minor allele signal intensities by the signal intensity
sum of both minor and major alleles at each SNP position. When these dots are placed across the chromosome, they look like tracks, and normal
chromosome regions have three tracks. LOH regions have only two tracks in this case because the sample is homogeneous for tumor. LOHs are
marked with orange color. Gain regions generate allelic imbalance, which is presented by four tracks
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OncoScan analysis has numerous quality control (QC)
metrics, some of which were developed and are being
used for previous versions of array platforms. Major
QC metrics include the Median of the Absolute
values of all Pairwise Differences between log2 ratios(MAPD), Normal Diploid Waviness Standard Devi-
ation (ndWavinessSD), and SNP Quality Control of
Normal Diploid Markers (ndSNPQC) [22]. MAPD
and ndWavinessSD represent short-range and long-range
noise levels, respectively; therefore, the lower these values,
the greater the quality of CNV estimation. Resolution of
Jung et al. Applied Cancer Research  (2017) 37:1 Page 7 of 8genotyping data is reflected by ndSNPQC, which is calcu-
lated by measuring distances between each genotype. High
ndSNPQC values indicate better identification of each
genotype and hence superior BAF results.
In addition several unique QC metrics for OncoS-
can are introduced [19]. One of them is the Cel-
PairCheck Status. OncoScan microarray analysis
utilizes two chips per sample; therefore, each sample
generates two data files (e.g., one CEL file from the
A/T nucleotide-gap filling reaction and the other file
from the G/C nucleotide-gap filling reaction). Cel-
PariCheck examines whether these two data sets are
generated from the identical sample using genotypes
of Signature SNPs incorporated into the microarrays.
If samples pass this QC test, there is no chance of
mispairing; otherwise, mispairing among samples
and/or data could have occurred. In addition, the
metric also determines assignment of AT or GC
channel results to its corresponding gap filling reac-
tion, and shows error messages if channels are not
properly assigned.
Clinical applications
OncoScan microarray analysis is deepening our
understanding of genetic variations in cancer. Re-
cently, in a renal carcinoma, OncoScan results
showed novel detection of copy-neutral LOH that had
been unavailable from previous diagnostic methods
including aCGH [9]. In a breast cancer, CNV detec-
tion by OncoScan was tested as a recurrence
biomarker [21]. In glioma, it was demonstrated that
OncoScan results could aide in detecting additional
genome-wide alteration such as gene amplifications
and rearrangements [3]. Our laboratory has validated
the OncoScan microarray as an additional tool for the
assessment of human cancers. The ability to detect
CNVs and SNPs has resulted in replacement of FISH
based assays for certain tumor types and targets.
Future directions
In an era of next generation sequencing (NGS) technol-
ogy which is widely used to detect somatic variations
such as SNPs and indels, most NGS assays focus on
targeted gene panels. To date NGS technologies have
had significant limitations with respect to CNV detec-
tion compared to microarray technologies [8, 23, 24].
Advances in NGS chemistries and analytics tools could
make NGS and microarray technologies very comple-
mentary and increase the number of variants detected in
human cancers [22, 24].
CNVs in most cases are interpreted as resulting in
gene expression level changes; gene overexpression can
be observed if the gene is located in a region of gain,
while lower or no gene expression can be observed if thegene is in a region of loss [25]. Gene expression profiling
could identify involved genes within large gain regions;
however, there could be discrepancies between the
degree of structural variation and gene expression levels
[1, 26, 27]. Gene expression profiling has discovered
novel cancer genes whose induction mechanisms are
independent of CNVs [27]. It may be that, for more
accurate cancer assessment, combined analysis of the
OncoScan results with whole exon expression profiling
or targeted RNA quantification would be a more ideal
approach.
Conclusions
OncoScan microarray analysis is a reliable assay to
assess human cancers for genome-wide copy number
changes. This assay circumvents previous obstacles
by combining a unique target generation system with
microarrays so that almost all types of solid cancer
samples can be analyzed in less than 48 h. The
analysis software is robust and user-friendly. Reso-
lution and somatic mutation detection could be fur-
ther enhanced by including additional CNV and
somatic mutation probes. The ability to detect and
accurately define regions of variation across the
genome will continue to be an important aspect of
precision medicine efforts.
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